The Supreme Court Struck Down IEEPA Tariffs – What Medtech Needs To Know
The U.S. Supreme Court recently marked a significant shift in the tariff landscape, learn what that means for your organization.
Global & Trade
Learn more about our Global Affairs work.
AdvaMed® Supports United States-Mexico-Canada Agreement Renewal
WASHINGTON—AdvaMed, the MedTech Association®, representing more than 650 medtech and health tech companies, the majority small businesses, today expressed support for renewal of the United States-Mexico-Canada Agreement (USMCA). Scott Whitaker,AdvaMed®…
AdvaMed® Plays Tariff Chess, Trump Plays Checkers
As tariff uncertainty continues in 2025,AdvaMed® plays tariff chess, advocating for predictable, zero-for-zero policies to protect medtech innovation and access.
AdvaMed® Advancements: Q4 2025 Report
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
AdvaMed® Calls U.S.-China Trade Announcement a “Positive Step” for U.S.-led Medtech
WASHINGTON—AdvaMed, the MedTech Association®, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally.
AdvaMed® Advancements: Q3 2025 Report
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment,AdvaMed® remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing…
The Economic Impact of the Medical Technology Industry 2024
Explore AdvaMed’s 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech’s vital contributions to the U.S. economy
AdvaMed® Responds to Commerce Department Section 232 National Security Investigation, Seeks Policies to Strengthen U.S. Position as Global Medtech Leader
WASHINGTON—AdvaMed, the MedTech Association®, today submitted formal comments responding to the U.S. Department of Commerce investigation into whether the U.S.’s current level of medtech imports has national security implications. The…
Supreme Court Term in Review: Implications for the Medical Technology Industry
Supreme Court Term in Review: Implications for the Medical Technology Industry
AdvaMed® Statement on Commerce Department Section 232 National Security Investigation
WASHINGTON—AdvaMed, the MedTech Association®, released the following statement from President and CEO Scott Whitaker on the Administration’s announcement of its investigation under Section 232 of the Trade Expansion Act into…